Innovation
Innovation drives disease prevention
We're uniting science, technology and talent to get ahead of RSV
RSV
0:31
Press releases
- GSK receives US FDA file acceptance for Jemperli (dostarlimab-gxly) plus chemotherapy for the treatment of dMMR/MSI-H primary advanced or recurrent endometrial cancer
- GSK announces the COiMMUNITY Initiative to help achieve higher adult vaccination rates in the US
- US FDA approves GSK’s AREXVY, the world’s first respiratory syncytial virus (RSV) vaccine for older adults


Choose your path
By bringing outstanding people together in an inclusive environment to do work that matters, we can impact the world’s health.
GSK Global links
Visit our Global site for additional features